

Seattle Genetics

[View the current Seattle Genetics Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/9307-Seattle+Genetics.html)

(<http://www.bioportfolio.com/biocorporate/9307-Seattle+Genetics.html>)

Contact Details:

22215 26th Avenue S. E.

Bothell

Washington

98021

United States of America

Tel: (425) 527-4000

Fax: (425) 527-4001

Email: contact@seagen.com

Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Our strategy is focused on advancing our portfolio of product candidates in diseases with unmet medical need and significant market potential. We have more than 150 employees and are located in a high-technology campus in Bothell, Washington, a suburb of Seattle.

Recent Publications by Seattle Genetics:



- [Potent antibody drug conjugates for cancer therapy.](#)
*Significant progress has been made in the past few years in the area of...*1st October, 2009
Seattle Genetics, Inc., 21823 30th Dr. SE, Bothell, WA 98021, United- Curr Opin Chem Biol. 2009 Jun;13(3):235-44. Epub 2009 May 4. ([DOI Direct Link](#))
- [Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis.](#)
*Rheumatoid arthritis (RA) is characterized by inflammation and cellular...*24th September, 2009
Department of Preclinical Therapeutics, Seattle Genetics, Bothell,- J Immunol. 2009 Sep 15;183(6):3770-7. Epub 2009 Aug 26. ([DOI Direct Link](#))
- [The pharmacologic basis for antibody-auristatin conjugate activity.](#)
*Antibody-drug conjugates (ADCs) made with auristatin antimetabolic agents...*22nd September, 2009
Seattle Genetics, Inc., 21823 30th Drive SE, Bothell, WA 98021, USA.- J Pharmacol Exp Ther. 2009 Sep;330(3):932-8. Epub 2009 Jun 4. ([DOI Direct Link](#))
- [Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases.](#)
*The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153,...*18th September, 2009
Department of Preclinical Therapeutics, Seattle Genetics, Inc, 21823 30th- Adv Exp Med Biol. 2009;647:174-85. ([DOI Direct Link](#))

- [Targeting CD70 for Human Therapeutic Use.](#)
*Expression of CD70, a member of the tumor necrosis factor superfamily, is...*18th September, 2009
Department of Preclinical Therapeutics, Seattle Genetics, Inc., Bothell,- Adv Exp Med Biol. 2009;647:108-19. ([DOI Direct Link](#))
- [Targeting of BAFF and APRIL for Autoimmunity and Oncology.](#)
*BLYS and APRIL are tumor necrosis factor superfamily members shown to be...*18th September, 2009
Seattle Genetics, Inc., 21823-30th Drive SE, Bothell, WA, 98021, USA,- Adv Exp Med Biol. 2009;647:52-63. ([DOI Direct Link](#))
- [Therapeutic Interventions Targeting CD40L \(CD154\) and CD40: The Opportunities and Challenges.](#)
*CD40 was originally identified as a receptor on B-cells that delivers...*18th September, 2009
Department of Preclinical Therapeutics, Seattle Genetics Inc., 21823 30th- Adv Exp Med Biol. 2009;647:8-36. ([DOI Direct Link](#))
- [Overview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets.](#)
*Since the discovery of tumor necrosis factor TNFalpha about 25 years ago,...*18th September, 2009
Department of Preclinical Therapeutics, Seattle Genetics, Inc., 21823 30th- Adv Exp Med Biol. 2009;647:1-7. ([DOI Direct Link](#))
- [Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.](#)
*Antibody-drug conjugates (ADCs) were prepared with potent camptothecin...*2nd September, 2009
Seattle Genetics, Inc., 21823 30th Drive SE, Bothell, Washington 98021,- Bioconjug Chem. 2009 Jun;20(6):1242-50. ([DOI Direct Link](#))
- [Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenstrom's macroglobulinemia.](#)
*Targeting leukocyte differentiation antigens is a validated approach to...*3rd July, 2009
Department of Preclinical Therapeutics, Seattle Genetics, Inc, Bothell, WA- Clin Lymphoma Myeloma. 2009 Mar;9(1):90-3. ([DOI Direct Link](#))
- [Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.](#)
*Cytotoxic agents streptonigrin and 17-amino-geldanamycin were linked to...*30th June, 2009
Seattle Genetics,- Bioorg Med Chem Lett. 2009 May 15;19(10):2650-3. Epub 2009 Apr 5. ([DOI Direct Link](#))
- [Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.](#)
*Despite major advances in the treatment of non-Hodgkin lymphoma (NHL),...*3rd June, 2009
Department of Preclinical Therapeutics, Seattle Genetics, Bothell, WA- Blood. 2009 Apr 30;113(18):4352-61. Epub 2009 Jan 15. ([DOI Direct Link](#))
- [Meeting report: drug carriers in medicine and biology.](#)
*Despite major advances in the treatment of non-Hodgkin lymphoma (NHL),...*24th March, 2009
Seattle Genetics,- Mol Pharm. 2009 Jan-Feb;6(1):82-5. ([DOI Direct Link](#))
- [Preclinical characterization of SGN-70, a humanized antibody directed against CD70.](#)
*PURPOSE: CD70 (CD27L) is a member of the tumor necrosis factor family...*6th February, 2009
Seattle Genetics, Inc., Bothell, Washington 98021, USA.- Clin Cancer Res. 2008 Dec 1;14(23):7763-72. ([DOI Direct Link](#))
- [Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.](#)
*SGN-40 is a therapeutic antibody targeting CD40, which induces potent...*31st January, 2009
Department of Preclinical Therapeutics, Seattle Genetics Inc., Seattle, WA- Br J Cancer. 2009 Jan 13;100(1):113-7. Epub 2008 Dec 9. ([DOI Direct Link](#))

Press Releases on Seattle Genetics:

deCODE Receives Delisting Notice From Nasdaq. Plans to Appeal	24th November, 2009	deCODE Genetics Inc	REYKJAVIK, Iceland, November 24 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it has received notice from the Nasdaq Stock Market that trading in the company
XanGo and Real Salt Lake Share International Spotlight In Major League Soccer Championship	24th November, 2009	XanGo, LLC	LEHI, Utah, Nov. 24 /PRNewswire/ -- Three-plus years ago, XanGo, LLC and Real Salt Lake celebrated a first in North American professional sports history, by inking a jersey-front sponsorship. Today,
Blue Marble Energy, OPDA Awarded \$2M by WA's Community Economic Revitalization Board	24th November, 2009	Blue Marble Energy Corp.	SEATTLE, Nov. 24 /PRNewswire/ -- Blue Marble Energy Corp. announced today that the company and the Odessa Public Development Authority (OPDA) were recently awarded \$2 million by Washington State's
deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court	24th November, 2009	DeCODE Genetics Inc	REYKJAVIK, Iceland, November 24 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced the approval of all of its "first day" motions by the U.S. Bankruptcy Court
5AM Solutions Launches Family Helix Community	24th November, 2009	5AM Solutions	RESTON, Va., Nov. 24 /PRNewswire/ -- Today, 5AM Solutions announced the launch of the Family Helix Community, an interactive web-based portal designed to facilitate collaboration and communication

BioNews Results for Seattle Genetics



- [Seattle Genetics \(SGEN\) Bearish Technical Alert - Trend Down 14.6...](#)
Zibb: Nov 11 2009 12:50AM Matching: seattle genetics
- [Alder and New Partner, Bristol, to Give Amgen and Abbott a Run for Their Money](#)
Xconomy: Nov 11 2009 2:57PM Matching: seattle genetics
- [Alder Rides Momentum of \\$1B Deal, Aims to Give Amgen and Abbott a Run for Their Money](#)
Xconomy: Nov 11 2009 7:40AM Matching: seattle genetics

- [Seattle Genetics \(SGEN\) Bearish Technical Alert - Trend Down 14.6%](#)
TradingMarkets: Nov 10 2009 11:42PM Matching: seattle genetics
- [San DiegoEURs PaxVax Developing Oral Tablet Vaccine, Looks to Raise More Cash With Support of Seattles Ignit](#)
Xconomy: Nov 9 2009 7:08PM Matching: seattle genetics
- [Seattle Genetics to Present at Upcoming Investor Conferences](#)
RBC Dain Rauscher: Oct 28 2009 10:37PM Matching: seattle genetics
- [Seattle Genetics Posts 3Q 2009 Financial Results](#)
Individual.com: Oct 28 2009 9:55AM Matching: seattle genetics
- [Seattle Genetics Posts 3Q 2009 Financial Results](#)
TradingMarkets: Oct 28 2009 5:05AM Matching: seattle genetics
- [Seattle Genetics reports its third-quarter financial results](#)
News-Medical.Net: Oct 24 2009 4:52AM Matching: seattle genetics
- [Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results](#)
Pharma Live: Oct 24 2009 5:29AM Matching: seattle genetics
- [News and FDA Updates for Seattle Genetics \(Nasdaq:SGEN\), Dynavax \(Nasdaq:DVAX\)](#)
American Chronicle: Oct 24 2009 9:45AM Matching: seattle genetics
- [Seattle Genetics reports its financial results for the third quarter and its recent progress](#)
News-Medical.Net: Oct 23 2009 11:07AM Matching: seattle genetics
- [Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results](#)
SmartBrief: Oct 23 2009 5:36AM Matching: seattle genetics
- [Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results](#)
Pharmacy Choice: Oct 23 2009 6:25AM Matching: seattle genetics
- [Seattle Genetics Q3 Loss Narrows On Higher Revenue - Update](#)
RTTNews.com: Oct 23 2009 2:40AM Matching: seattle genetics

Seattle Genetics Clinical Trials:



- [A Safety Study in Patients With Chronic Lymphocytic Leukemia](#)

Seattle Genetics Patents:



- 7553816- [p-amidobenzylethers in drug delivery agents](#)
- 6843989- [Methods for the treatment and prevention of cancer using anti-CD40 antibodies](#)
- 6884869- [Pentapeptide compounds and uses related thereto](#)
- 6946129- [Recombinant anti-CD40 antibody and uses thereof](#)
- 7090843- [Recombinant anti-CD30 antibodies and uses thereof](#)

- 7091186- [p-Amidobenzylethers in drug delivery agents](#)
- 7098308- [Pentapeptide compounds and uses related thereto](#)
- 7256257- [Pentapeptide compounds and uses related thereto](#)
- 7423116- [Pentapeptide compounds and uses related thereto](#)
- 7491390- [Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders](#)
- 7498032- [Methods for treating immune disorders or cancer with anti-CD40 antibodies](#)
- 7498298- [Monomethylvaline compounds capable of conjugation to ligands](#)
- 7510711- [Methods for the treatment of cancer using anti-CD40 antibodies](#)
- 6838261- [Nucleic acids encoding anti-CD40 proteins and methods of producing recombinant anti-CD40 proteins](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

